To examine the role of KMT2C alterations in gastrointestinal cancers and their impact on enhancer networks and clinical outcomes, specifically focusing on the types of outcomes assessed.
Key Findings:
KMT2C is frequently altered in gastrointestinal malignancies through loss-of-function variants and structural alterations.
KMT2C deficiency destabilizes enhancer and super-enhancer networks, leading to large-scale transcriptional rewiring.
Alterations in KMT2C are linked to tumor mutational burden, microsatellite instability, immune infiltration patterns, and responses to immune checkpoint blockade.
KMT2C dysfunction can reshape the tumor immune microenvironment and contribute to therapeutic vulnerabilities.
Interpretation:
The biological impact of KMT2C alterations is influenced by mutation class, co-occurring genomic lesions, and tissue-specific transcriptional circuitry.
Limitations:
The review does not provide direct clinical recommendations or implications for practice.
The complexity of KMT2C's role in various cancers may limit generalizability of findings.
Conclusion:
KMT2C alterations represent significant epigenetic changes that affect gastrointestinal cancer progression.
